Compare Biogen Inc (BIIB) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs GoPro Inc — how do they compare? Biogen Inc trades at $206.76 (market cap $30.13B), while GoPro Inc trades at $0.58 (market cap $114.41M). The key difference: Biogen Inc is far larger — about 263.4× GoPro Inc's market cap, and Biogen Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | GPRO | |
|---|---|---|
Market Cap | $30.13B | $114.41M |
Sector | Health | Technology |
52-Week High | $216.63 | $2.88 |
52-Week Low | $128.93 | $0.62 |
Enterprise Value | $37.20B | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
GoPro (GPRO) trades at $0.57, down 18.48% in the last session, reflecting ongoing operational challenges. The company shows deteriorating fundamentals with negative net income margins (-28.52%) and consecutive earnings misses. Technical indicators signal bearish momentum, while cash flow remains negative. Recent news highlights a strategic review process for potential sale alternatives as the company faces significant financial stress.
The outlook remains highly speculative with substantial execution risks. Investment opportunity hinges entirely on successful strategic alternatives, while risks include persistent cash burn, competitive pressures, and potential dilution from recent financing. The stock presents a binary outcome scenario dependent on corporate action success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
